Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRIUS-LN
2020-005830-14Phase 3Active
- Sponsor
- Novartis
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) comparing ianalumab + standard-of-care therapy with placebo + standard-of-care therapy (2 arms). Primary endpoint: Stable complete renal response at Week 72. Started Jan 2022; status: active.
02
Drugs
ianalumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2020-005830-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005830-14.